136 related articles for article (PubMed ID: 27123883)
1. Systemic therapy for recurrent meningioma.
Le Rhun E; Taillibert S; Chamberlain MC
Expert Rev Neurother; 2016 Aug; 16(8):889-901. PubMed ID: 27123883
[TBL] [Abstract][Full Text] [Related]
2. Biology and clinical management challenges in meningioma.
Mawrin C; Chung C; Preusser M
Am Soc Clin Oncol Educ Book; 2015; ():e106-15. PubMed ID: 25993161
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs.
Dasanu CA; Alvarez-Argote J; Limonadi FM; Codreanu I
Expert Opin Biol Ther; 2019 Feb; 19(2):99-104. PubMed ID: 30556741
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?
Dasanu CA; Samara Y; Codreanu I; Limonadi FM; Hamid O; Alvarez-Argote J
J Oncol Pharm Pract; 2019 Apr; 25(3):638-647. PubMed ID: 30253729
[TBL] [Abstract][Full Text] [Related]
5. Emerging systemic treatment options in meningioma.
Mair MJ; Berghoff AS; Brastianos PK; Preusser M
J Neurooncol; 2023 Jan; 161(2):245-258. PubMed ID: 36181606
[TBL] [Abstract][Full Text] [Related]
6. The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma.
Chamberlain MC
Curr Opin Oncol; 2012 Nov; 24(6):666-71. PubMed ID: 22759739
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
Furtner J; Schöpf V; Seystahl K; Le Rhun E; Rudà R; Roelcke U; Koeppen S; Berghoff AS; Marosi C; Clement P; Faedi M; Watts C; Wick W; Soffietti R; Weller M; Preusser M
Neuro Oncol; 2016 Mar; 18(3):401-7. PubMed ID: 26354929
[TBL] [Abstract][Full Text] [Related]
8. Medical treatment of recurrent meningiomas.
Chamberlain MC; Barnholtz-Sloan JS
Expert Rev Neurother; 2011 Oct; 11(10):1425-32. PubMed ID: 21955199
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic treatment of meningiomas.
Preusser M; Marosi C
Curr Treat Options Neurol; 2015 Jul; 17(7):359. PubMed ID: 25975819
[TBL] [Abstract][Full Text] [Related]
11. The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review.
Scerrati A; Mongardi L; Visani J; Lofrese G; Cavallo MA; Fiorentino A; De Bonis P
Expert Rev Anticancer Ther; 2020 Mar; 20(3):197-203. PubMed ID: 32116057
[No Abstract] [Full Text] [Related]
12. Improvement in Visual Fields After Treatment of Intracranial Meningioma With Bevacizumab.
Ly KI; Hamilton SR; Rostomily RC; Rockhill JK; Mrugala MM
J Neuroophthalmol; 2015 Dec; 35(4):382-6. PubMed ID: 26049681
[TBL] [Abstract][Full Text] [Related]
13. Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
Karsy M; Guan J; Cohen A; Colman H; Jensen RL
Neurosurg Clin N Am; 2016 Apr; 27(2):249-60. PubMed ID: 27012389
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
[TBL] [Abstract][Full Text] [Related]
15. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
Nassehi D
Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
[TBL] [Abstract][Full Text] [Related]
16. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
Chamberlain MC; Glantz MJ; Fadul CE
Neurology; 2007 Sep; 69(10):969-73. PubMed ID: 17785665
[TBL] [Abstract][Full Text] [Related]
17. Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.
Gupta V; Samuleson CG; Su S; Chen TC
Neurosurg Focus; 2007; 23(4):E9. PubMed ID: 17961046
[TBL] [Abstract][Full Text] [Related]
18. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
[TBL] [Abstract][Full Text] [Related]
19. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
[TBL] [Abstract][Full Text] [Related]
20. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
